Improving Outcomes in Primary CNS Lymphoma

Publication date: Available online 21 July 2018Source: Best Practice & Research Clinical HaematologyAuthor(s): Maya S. Graham, Lisa M. DeAngelisAbstractPrimary central nervous system lymphoma (PCNSL) is an aggressive disease with previously poor prognosis. The advent of high-dose methotrexate-based induction regimens as well as use of consolidation therapy has greatly improved this prognosis in recent decades, but durable remission still eludes half of patients. In this review, we summarize the progress made in the treatment of PCNSL as well as the challenges that remain, with a focus on defining optimal induction and consolidation regimens, including the promise of developing biotherapies. Future studies will help delineate the best combination of existing and novel treatment strategies, with the goal of expanding the cohort of patients achieving a cure.
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research